Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Stoke Therapeutics stock

Learn how to easily invest in Stoke Therapeutics stock.

Stoke Therapeutics Inc is a biotechnology business based in the US. Stoke Therapeutics shares (STOK) are listed on the NASDAQ and all prices are listed in US Dollars. Stoke Therapeutics employs 102 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Stoke Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – STOK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Stoke Therapeutics stock price (NASDAQ: STOK)

Use our graph to track the performance of STOK stocks over time.

Stoke Therapeutics shares at a glance

Information last updated 2022-07-02.
Latest market close$13.77
52-week range$9.55 - $34.83
50-day moving average $13.44
200-day moving average $20.03
Wall St. target price$54.89
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.54

Buy Stoke Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Stoke Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Stoke Therapeutics price performance over time

Historical closes compared with the close of $13.77 from 2022-07-01

1 week (2022-06-28) 6.25%
1 month (2022-06-01) 14.46%
3 months (2022-04-01) N/A
6 months (2022-01-05) -33.96%
1 year (2021-07-02) -59.24%
2 years (2020-07-02) -40.18%
3 years (2019-07-05) 28
5 years (2017-07-01) N/A

Stoke Therapeutics financials

Revenue TTM $3 million
Gross profit TTM $0
Return on assets TTM -19.76%
Return on equity TTM -36.56%
Profit margin 0%
Book value $6.15
Market capitalisation $539.6 million

TTM: trailing 12 months

Stoke Therapeutics share dividends

We're not expecting Stoke Therapeutics to pay a dividend over the next 12 months.

Have Stoke Therapeutics's shares ever split?

Stoke Therapeutics's shares were split on a 1:9 basis on 5 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Stoke Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Stoke Therapeutics shares which in turn could have impacted Stoke Therapeutics's share price.

Stoke Therapeutics share price volatility

Over the last 12 months, Stoke Therapeutics's shares have ranged in value from as little as $9.545 up to $34.83. A popular way to gauge a stock's volatility is its "beta".

STOK.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Stoke Therapeutics's is 0.656. This would suggest that Stoke Therapeutics's shares are less volatile than average (for this exchange).

Stoke Therapeutics overview

Stoke Therapeutics, Inc. , an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Stoke Therapeutics is owned by insiders or institutions?
Currently 6.292% of Stoke Therapeutics shares are held by insiders and 105.741% by institutions.
How many people work for Stoke Therapeutics?
Latest data suggests 102 work at Stoke Therapeutics.
When does the fiscal year end for Stoke Therapeutics?
Stoke Therapeutics's fiscal year ends in December.
Where is Stoke Therapeutics based?
Stoke Therapeutics's address is: 45 Wiggins Avenue, Bedford, MA, United States, 01730
What is Stoke Therapeutics's ISIN number?
Stoke Therapeutics's international securities identification number is: US86150R1077
What is Stoke Therapeutics's CUSIP number?
Stoke Therapeutics's Committee on Uniform Securities Identification Procedures number is: 86149C104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site